Arana's pilot for arthritis
Wednesday, 26 November, 2008
Arana Therapeutics has sought approval for a small dose regimen study of its lead inflammatory disease candidate ART621 in rheumatoid arthritis.
The study, to be conducted in Sri Lanka and enrolling 20 patients, will compare four different dose regimens in order to optimise the regimen for its international Phase II dose ranging study.
Arana’s acting CEO Dr Steffen Nock said in an ASX statement that the data gathered from the small study will help fine-tune the larger one.
He said data from the company’s study of ART621 in psoriasis was due early next year.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
